Pdb67 Economic Evaluation of Type 2 Diabetes - Impact of Pricing and Reimbursement Reforms

Ilavska, A; Glatz, P. C.; Hloska, Adam; Filko, Martin

doi:10.1016/s1098-3015(10)72311-1

Search citation statements

Order By: Relevance

Paper Sections

Select...

Evaluation Of Dm Pharmacotherapeutic Direct Costs1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of DM in the Slovak republic is higher if compared with other European countries. Most patients suffer DM2 and are in the fifth and sixth decennium (52%) [14,15].…”

Section: Evaluation Of Dm Pharmacotherapeutic Direct Costsmentioning

confidence: 99%

Relationship between clinical effectiveness and pharmacoeconomic cost in patients with diabetes mellitus

Ilavska¹,

Cviková²,

Šimúnová³

et al. 2011

Acta Facultatis Pharmaceuticae Universitatis Comenianae

View full text Add to dashboard Cite

Therapeutic practices and effectiveness have a crucial impact on healthcare system costs in diabetes mellitus treatment with significant economic implications. Encompassing up to 15% of the healthcare budget in the Slovak Republic, diabetes mellitus imposes a huge economic burden on the Slovak healthcare system.The paper analyzes the treatment needs and medication costs for diabetes between 2004 and 2010 in the Slovak Republic. Both insulin and oral antidiabetic therapy are available for all patients depending on the severity of the disease. The costs analysis clearly indicates a great impact of diabetology on healthcare. The results of this work have confirmed that diabetes mellitus is a costly disease, and the costs are expected to grow further. With respect to the increasing demand and limited resources, there is a growing need for additional economic analyses. To achieve control of costs in the decision making processes in the Slovak Republic, the role of pharmacoeconomics should be strengthened.

show abstract

“…The prevalence of DM in the Slovak republic is higher if compared with other European countries. Most patients suffer DM2 and are in the fifth and sixth decennium (52%) [14,15].…”

Section: Evaluation Of Dm Pharmacotherapeutic Direct Costsmentioning

confidence: 99%